Literature DB >> 24943493

A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.

Carlos Gomez-Martín1, Fernando Lopez-Rios2, Jorge Aparicio3, Jorge Barriuso4, Rocio García-Carbonero5, Roberto Pazo6, Fernando Rivera7, Mercedes Salgado8, Antonieta Salud9, Enrique Vázquez-Sequeiros10, Florian Lordick11.   

Abstract

Identification of the importance of human epidermal growth factor receptor-2 (HER2) status, biomarker testing and the development of anti-HER2 treatments have changed the prognosis of breast and gastric cancers. The addition of trastuzumab to chemotherapy has improved outcomes for patients with HER2-positive metastatic adenocarcinoma of the stomach and gastroesophageal junction, but some relevant issues remain to be elucidated or will emerge with new drugs. This article reviews the current state of HER2 in gastric cancer focusing on diagnostic and anti-HER2 targeted treatment issues and the role of trastuzumab in localized disease, and its combination or integration with new therapies.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Gastric cancer; HER2; Review; Trastuzumab

Mesh：

Substances：

Year:  2014        PMID： 24943493     DOI： 10.1016/j.canlet.2014.05.019

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  33 in total

1.  Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling.

Authors:  Yan Cui; Shao-Bo Li; Xing-Chun Peng; Jun Wu; Guo-Hui Fu
Journal:  Dig Dis Sci       Date:  2015-07-15       Impact factor: 3.199

2.  Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.

Authors:  Jun Zhou; Zhi Peng; Yi Liu; Jifang Gong; Xiaotian Zhang; Ming Lu; Jing Gao; Yili Li; Yanyan Li; Lin Shen
Journal:  J Gastroenterol       Date:  2015-02-22       Impact factor: 7.527

3.  MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.

Authors:  L Venturutti; R I Cordo Russo; M A Rivas; M F Mercogliano; F Izzo; R H Oakley; M G Pereyra; M De Martino; C J Proietti; P Yankilevich; J C Roa; P Guzmán; E Cortese; D H Allemand; T H Huang; E H Charreau; J A Cidlowski; R Schillaci; P V Elizalde
Journal:  Oncogene       Date:  2016-05-09       Impact factor: 9.867

Review 4.  [Current biomarkers for gastric cancer].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2017-03       Impact factor: 1.011

5.  Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.

Authors:  Q Li; H Li; H Jiang; Y Feng; Y Cui; Y Wang; Y Ji; Y Yu; W Li; C Xu; S Yu; R Zhuang; T Liu
Journal:  Clin Transl Oncol       Date:  2017-11-22       Impact factor: 3.405

6.  A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy.

Authors:  Qian Li; Minzhi Lv; Huiqin Jiang; Yan Wang; Shan Yu; Wei Li; Yiyi Yu; Tianshu Liu
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-30       Impact factor: 4.553

Review 7.  Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.

Authors:  Conor A Bradley; Manuel Salto-Tellez; Pierre Laurent-Puig; Alberto Bardelli; Christian Rolfo; Josep Tabernero; Hajrah A Khawaja; Mark Lawler; Patrick G Johnston; Sandra Van Schaeybroeck
Journal:  Nat Rev Clin Oncol       Date:  2017-04-04       Impact factor: 66.675

Review 8.  Immune Therapy in GI Malignancies: A Review.

Authors:  Judy Wang; Kim A Reiss; Rina Khatri; Elizabeth Jaffee; Dan Laheru
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

9.  Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis.

Authors:  L Venturutti; L V Romero; A J Urtreger; M F Chervo; R I Cordo Russo; M F Mercogliano; G Inurrigarro; M G Pereyra; C J Proietti; F Izzo; M C Díaz Flaqué; V Sundblad; J C Roa; P Guzmán; E D Bal de Kier Joffé; E H Charreau; R Schillaci; P V Elizalde
Journal:  Oncogene       Date:  2015-07-27       Impact factor: 9.867

10.  Evaluation of a trastuzumab-containing treatment regimen for patients with unresectable advanced or recurrent gastric cancer.

Authors:  Tsutomu Namikawa; Eri Munekage; Masaya Munekage; Hiromichi Maeda; Tomoaki Yatabe; Hiroyuki Kitagawa; Kouichi Sakamoto; Masayuki Obatake; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  Mol Clin Oncol       Date:  2016-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.